Kairos Pharma (NYSEAMERICAN:KAPA) Trading 4.7% Higher – Time to Buy?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) rose 4.7% during mid-day trading on Monday . The company traded as high as $1.86 and last traded at $1.84. 53,437 shares changed hands during trading, a decline of 34% from the average session volume of 81,344 shares. The stock had previously closed at $1.7580.

Kairos Pharma Trading Down 1.9%

The firm has a 50 day moving average of $2.11 and a two-hundred day moving average of $3.16. The stock has a market capitalization of $6.15 million, a PE ratio of -0.93 and a beta of 1.48.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.42) earnings per share for the quarter. Equities research analysts forecast that Kairos Pharma, Ltd. will post -2.59 EPS for the current year.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.